Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics

Blocking adenine synthesis sensitizes some triple-negative breast cancer cells to apoptotic death. Depleting adenine to prime for apoptosis Triple-negative breast cancers (TNBCs) are notoriously difficult to treat. Daniels et al. identified a metabolic vulnerability in TNBC patient cells and cell lines that may create a therapeutic opportunity in patients. The authors searched for metabolism-perturbing small-molecule compounds that sensitized TNBC lines to apoptosis induced by BH3 mimetics that block antiapoptotic proteins. They found that inhibition of NAMPT, the rate-limiting enzyme of the NAD+ salvage pathway, and specifically the loss of adenine downstream of NAMPT inhibition primed TNBC cells for apoptotic death. The findings suggest that combining NAMPT inhibitors with BH3 mimetics might be effective in some patients with TNBC. Cancer cells have differential metabolic dependencies compared to their nonmalignant counterparts. However, few metabolism-targeting compounds have been successful in clinical trials. Here, we investigated the metabolic vulnerabilities of triple-negative breast cancer (TNBC), particularly those metabolic perturbations that increased mitochondrial apoptotic priming and sensitivity to BH3 mimetics (drugs that antagonize antiapoptotic proteins). We used high-throughput dynamic BH3 profiling (HT-DBP) to screen a library of metabolism-perturbing small molecules, which revealed inhibitors of the enzyme nicotinamide phosphoribosyltransferase (NAMPT) as top candidates. In some TNBC cells but not in nonmalignant cells, NAMPT inhibitors increased overall apoptotic priming and induced dependencies on specific antiapoptotic BCL-2 family members. Treatment of TNBC cells with NAMPT inhibitors sensitized them to subsequent treatment with BH3 mimetics. The combination of a NAMPT inhibitor (FK866) and an MCL-1 antagonist (S63845) reduced tumor growth in a TNBC patient–derived xenograft model in vivo. We found that NAMPT inhibition reduced NAD+ concentrations below a critical threshold that resulted in depletion of adenine, which was the metabolic trigger that primed TNBC cells for apoptosis. These findings demonstrate a close interaction between metabolic and mitochondrial apoptotic signaling pathways and reveal that exploitation of a tumor-specific metabolic vulnerability can sensitize some TNBC to BH3 mimetics.

[1]  A. Carnero,et al.  NAD+ metabolism, stemness, the immune response, and cancer , 2021, Signal Transduction and Targeted Therapy.

[2]  Jefte M. Drijvers,et al.  Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8+ T Cells , 2020, Cancer Immunology Research.

[3]  A. Letai,et al.  Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer , 2020, Breast cancer research : BCR.

[4]  Xu Luo,et al.  Faculty Opinions recommendation of BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[5]  A. Letai,et al.  High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors , 2020, Science Signaling.

[6]  S. Benkovic,et al.  Metabolomics and mass spectrometry imaging reveal channeled de novo purine synthesis in cells , 2020, Science.

[7]  Damien Y. Duveau,et al.  Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening , 2019, Science Translational Medicine.

[8]  Claire O'Donovan,et al.  MetaboLights: a resource evolving in response to the needs of its scientific community , 2019, Nucleic Acids Res..

[9]  A. Letai,et al.  BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics , 2019, Cell Death & Differentiation.

[10]  John G Doench,et al.  Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. , 2019, Cell metabolism.

[11]  V. Bafna,et al.  NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling , 2019, Nature.

[12]  B. Daignan-Fornier,et al.  Dual control of NAD+ synthesis by purine metabolites in yeast , 2019, eLife.

[13]  Keisuke Hikosaka,et al.  NAD Metabolism in Cancer Therapeutics , 2018, Front. Oncol..

[14]  A. Strasser,et al.  BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. , 2018, Cancer cell.

[15]  A. Strasser,et al.  Humanized Mcl-1 mice enable accurate pre-clinical evaluation of MCL-1 inhibitors destined for clinical use , 2018, bioRxiv.

[16]  Jing Yang,et al.  Expression of long non-coding RNA and mRNA in the hippocampus of mice with type 2 diabetes , 2018, Molecular medicine reports.

[17]  Lorin Crawford,et al.  Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity , 2018, Nature Communications.

[18]  S. Imai,et al.  Faculty of 1000 evaluation for NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. , 2018 .

[19]  D. Xing,et al.  Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer , 2018, Cell Death & Disease.

[20]  David S. Wishart,et al.  HMDB 4.0: the human metabolome database for 2018 , 2017, Nucleic Acids Res..

[21]  J. Montero,et al.  Why do BCL-2 inhibitors work and where should we use them in the clinic? , 2017, Cell Death and Differentiation.

[22]  J. Asara,et al.  The mTORC1 Signaling Network Senses Changes in Cellular Purine Nucleotide Levels. , 2017, Cell reports.

[23]  K. Glaser,et al.  Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation. , 2017, Biochemical and biophysical research communications.

[24]  J. Visvader,et al.  Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer , 2017, Science Translational Medicine.

[25]  Xin Gao,et al.  Physiologic Medium Rewires Cellular Metabolism and Reveals Uric Acid as an Endogenous Inhibitor of UMP Synthase , 2017, Cell.

[26]  H. Busch,et al.  Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells , 2017, Oncotarget.

[27]  S. Benkovic,et al.  A New View into the Regulation of Purine Metabolism: The Purinosome. , 2017, Trends in biochemical sciences.

[28]  F. Sotgia,et al.  Cancer metabolism: a therapeutic perspective , 2017, Nature Reviews Clinical Oncology.

[29]  M. V. Vander Heiden,et al.  Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin. , 2016, Cell metabolism.

[30]  A. Letai,et al.  Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. , 2016, Cancer discovery.

[31]  A. Letai,et al.  iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry , 2016, Biological chemistry.

[32]  C. Klemke,et al.  Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma: A Phase 2 Clinical Trial. , 2016, JAMA dermatology.

[33]  A. Letai,et al.  The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. , 2016, Blood.

[34]  G. Gordon,et al.  Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. , 2016, The Lancet. Oncology.

[35]  A. Letai,et al.  Mitochondria-Judges and Executioners of Cell Death Sentences. , 2016, Molecular cell.

[36]  Birgit Kasch,et al.  Next Generation , 2005, Im OP.

[37]  Xiao-Nan Li,et al.  Targeting metabolism in breast cancer: How far we can go? , 2016, World journal of clinical oncology.

[38]  J. Waring,et al.  Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study , 2015, Cancer Chemotherapy and Pharmacology.

[39]  W. Kiess,et al.  Physiological and pathophysiological roles of NAMPT and NAD metabolism , 2015, Nature Reviews Endocrinology.

[40]  J. Auwerx,et al.  NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. , 2015, Cell metabolism.

[41]  A. Nikiforov,et al.  The human NAD metabolome: Functions, metabolism and compartmentalization , 2015, Critical reviews in biochemistry and molecular biology.

[42]  J. Chi,et al.  Alternative Fuels for Cancer Cells , 2015, Cancer journal.

[43]  Karen Cichowski,et al.  Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.

[44]  E. Chini,et al.  Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors , 2013, Clinical Cancer Research.

[45]  A. Letai,et al.  BH3 profiling in whole cells by fluorimeter or FACS. , 2013, Methods.

[46]  D. Vitkup,et al.  Heterogeneity of tumor-induced gene expression changes in the human metabolic network , 2013, Nature Biotechnology.

[47]  M. Tan,et al.  Targeting cellular metabolism to improve cancer therapeutics , 2013, Cell Death and Disease.

[48]  A. Letai,et al.  Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML , 2012, Cell.

[49]  M. Ziegler,et al.  The NAD metabolome — a key determinant of cancer cell biology , 2012, Nature Reviews Cancer.

[50]  A. Ashworth,et al.  Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells , 2012, EMBO molecular medicine.

[51]  A. Letai,et al.  Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.

[52]  Mark T. W. Ebbert,et al.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.

[53]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[54]  C. Rudin,et al.  Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  R. Larsson,et al.  Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data , 2010, Cancer Chemotherapy and Pharmacology.

[56]  A. Ballestrero,et al.  Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE , 2009, PloS one.

[57]  S. Adams,et al.  Multiplexed assay panel of cytotoxicity in HK-2 cells for detection of renal proximal tubule injury potential of compounds. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[58]  A. Strasser,et al.  Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics , 2009, Nature Reviews Cancer.

[59]  A. Letai,et al.  Control of mitochondrial apoptosis by the Bcl-2 family , 2009, Journal of Cell Science.

[60]  S. Armstrong,et al.  BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. , 2008, Blood.

[61]  A. Letai,et al.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. , 2007, Cancer cell.

[62]  Ying Zhang,et al.  HMDB: the Human Metabolome Database , 2007, Nucleic Acids Res..

[63]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[64]  Michael P. Lisanti,et al.  Cancer metabolism: a therapeutic perspective , 2017, Nature Reviews Clinical Oncology.

[65]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[66]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[67]  C. Williamson,et al.  Therapeutic perspective. , 1951, California medicine.